| 1. |
|
|
| 2. |
- DeCarolis, Joseph, et al.
(författare)
-
Leveraging Open-Source Tools for Collaborative Macro-energy System Modeling Efforts
- 2020
-
Ingår i: Joule. - : Elsevier BV. - 2542-4351. ; 4:12, s. 2523-2526
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- The authors are founding team members of a new effort to develop an Open Energy Outlook for the United States. The effort aims to apply best practices of policy-focused energy system modeling, ensure transparency, build a networked community, and work toward a common purpose: examining possible US energy system futures to inform energy and climate policy efforts. Individual author biographies can be found on the project website: https://openenergyoutlook.org/. DeCarolis et al. articulate the benefits of forming collaborative teams with a wide array of disciplinary and domain expertise to conduct analysis with macro-energy system models. Open-source models, tools, and datasets underpin such efforts by enabling transparency, accessibility, and replicability among team members and with the broader modeling community.
|
|
| 3. |
- Battaglia, Manuela, et al.
(författare)
-
Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes
- 2020
-
Ingår i: Diabetes Care. - : American Diabetes Association. - 1935-5548 .- 0149-5992. ; 43:1, s. 5-12
-
Tidskriftsartikel (refereegranskat)abstract
- The clinical diagnosis of new-onset type 1 diabetes has, for many years, been considered relatively straightforward. Recently, however, there is increasing awareness that within this single clinical phenotype exists considerable heterogeneity: disease onset spans the complete age range; genetic susceptibility is complex; rates of progression differ markedly, as does insulin secretory capacity; and complication rates, glycemic control, and therapeutic intervention efficacy vary widely. Mechanistic and immunopathological studies typically show considerable patchiness across subjects, undermining conclusions regarding disease pathways. Without better understanding, type 1 diabetes heterogeneity represents a major barrier both to deciphering pathogenesis and to the translational effort of designing, conducting, and interpreting clinical trials of disease-modifying agents. This realization comes during a period of unprecedented change in clinical medicine, with increasing emphasis on greater individualization and precision. For complex disorders such as type 1 diabetes, the option of maintaining the "single disease" approach appears untenable, as does the notion of individualizing each single patient's care, obliging us to conceptualize type 1 diabetes less in terms of phenotypes (observable characteristics) and more in terms of disease endotypes (underlying biological mechanisms). Here, we provide our view on an approach to dissect heterogeneity in type 1 diabetes. Using lessons from other diseases and the data gathered to date, we aim to delineate a roadmap through which the field can incorporate the endotype concept into laboratory and clinical practice. We predict that such an effort will accelerate the implementation of precision medicine and has the potential for impact on our approach to translational research, trial design, and clinical management.
|
|
| 4. |
|
|
| 5. |
- Poulose, Simi, et al.
(författare)
-
A Green High Barrier Solution for Paperboard Packaging based on Potato Fruit Juice, Poly(lactic acid), and Poly(butylene adipate terephthalate)
- 2022
-
Ingår i: ACS APPLIED POLYMER MATERIALS. - : American Chemical Society (ACS). - 2637-6105. ; 4:6, s. 4179-4188
-
Tidskriftsartikel (refereegranskat)abstract
- The potential of using potato fruit juice (PFJ), a byproduct from the potato starch industry, was investigated as a barrier paper-coating material. The paperboard was initially hand-coated with PFJ (with and without glycerol as plasticizer) and then extrusioncoated with poly(lactic acid) (PLA) or a blend of PLA and poly(butylene adipate terephthalate) (PBAT). The multilayer coated paperboard was homogeneous in appearance with a glossy finish. The coated paperboard showed, at the most, a ca. 95% reduction in specific water vapor transmission rate compared to the uncoated paperboard. In the presence of the PFJ layer, the extrusion-coated paperboard experienced, at the most, a 98% reduction in oxygen permeability. The grease resistance of the paperboard was also improved significantly with this multilayer coating. PLA- and PFJ-coated samples showed better barrier properties, whereas PFJ with PLA/PBAT layers exhibited better adhesion and heat-sealing properties. The peel strength of the coated samples was moderately good for paper converting applications. The developed coated paperboard also exhibited good creasing properties which is yet again an advantage for packaging applications. The presented barrier properties make the developed multilayer coatings on paperboards a sustainable competitive alternative to several of today's coatings. KEYWORDS: paper coating, barrier coating, bio-based coating, potato fruit juice, poly(lactic acid), poly(butylene adipate terephthalate), barrier properties, peel strength, heat sealing
|
|
| 6. |
- Poulose, Simi, et al.
(författare)
-
Bioplastic films with unusually good oxygen barrier properties based on potato fruit-juice
- 2021
-
Ingår i: RSC Advances. - : Royal Society of Chemistry (RSC). - 2046-2069. ; 11:21, s. 12543-12548
-
Tidskriftsartikel (refereegranskat)abstract
- In this study, the use of potato fruit juice (PFJ) to make plastic films is presented. PFJ is an interesting raw material as it is obtained as a by-product from the potato-starch industry. The films showed uniquely high oxygen barrier properties, and the PFJ material is therefore a potential replacement for the most commonly used, expensive and petroleum-based ethylene-vinyl alcohol copolymer (EVOH) as a barrier layer in future packaging. The films also exhibit good grease resistance. As expected for hydrophilic materials, they exhibited high water vapour transmission rate, which shows that they, as for EVOH, have to be laminated with hydrophobic polymers in food packaging. The films, having a glass transition temperature between -5 degrees C and 10 degrees C, showed elastic-plastic behaviour with stable crack growth.
|
|
| 7. |
- Taylor, Peter N, et al.
(författare)
-
C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis
- 2023
-
Ingår i: The Lancet Diabetes and Endocrinology. - : Elsevier. - 2213-8587 .- 2213-8595. ; 11:12, s. 915-925
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Metabolic outcomes in type 1 diabetes remain suboptimal. Disease modifying therapy to prevent β-cell loss presents an alternative treatment framework but the effect on metabolic outcomes is unclear. We, therefore, aimed to define the relationship between insulin C-peptide as a marker of β-cell function and metabolic outcomes in new-onset type 1 diabetes.Methods: 21 trials of disease-modifying interventions within 100 days of type 1 diabetes diagnosis comprising 1315 adults (ie, those 18 years and older) and 1396 children (ie, those younger than 18 years) were combined. Endpoints assessed were stimulated area under the curve C-peptide, HbA1c, insulin use, hypoglycaemic events, and composite scores (such as insulin dose adjusted A1c, total daily insulin, U/kg per day, and BETA-2 score). Positive studies were defined as those meeting their primary endpoint. Differences in outcomes between active and control groups were assessed using the Wilcoxon rank test.Findings: 6 months after treatment, a 24·8% greater C-peptide preservation in positive studies was associated with a 0·55% lower HbA1c (p<0·0001), with differences being detectable as early as 3 months. Cross-sectional analysis, combining positive and negative studies, was consistent with this proportionality: a 55% improvement in C-peptide preservation was associated with 0·64% lower HbA1c (p<0·0001). Higher initial C-peptide levels and greater preservation were associated with greater improvement in HbA1c. For HbA1c, IDAAC, and BETA-2 score, sample size predictions indicated that 2-3 times as many participants per group would be required to show a difference at 6 months as compared with C-peptide. Detecting a reduction in hypoglycaemia was affected by reporting methods.Interpretation: Interventions that preserve β-cell function are effective at improving metabolic outcomes in new-onset type 1 diabetes, confirming their potential as adjuncts to insulin. We have shown that improvements in HbA1c are directly proportional to the degree of C-peptide preservation, quantifying this relationship, and supporting the use of C-peptides as a surrogate endpoint in clinical trials.
|
|
| 8. |
|
|
| 9. |
- Vilar, M, et al.
(författare)
-
Ligand-independent signaling by disulfide-crosslinked dimers of the p75 neurotrophin receptor
- 2009
-
Ingår i: Journal of cell science. - : The Company of Biologists. - 1477-9137 .- 0021-9533. ; 122:18Pt 18, s. 3351-3357
-
Tidskriftsartikel (refereegranskat)abstract
- Dimerization is recognized as a crucial step in the activation of many plasma membrane receptors. However, a growing number of receptors pre-exist as dimers in the absence of ligand, indicating that, although necessary, dimerization is not always sufficient for signaling. The p75 neurotrophin receptor (p75NTR) forms disulfide-linked dimers at the cell surface independently of ligand binding through Cys257 in its transmembrane domain. Here, we show that crosslinking of p75NTR dimers by cysteine-scanning mutagenesis results in constitutive, ligand-independent activity in several pathways that are normally engaged upon neurotrophin stimulation of native receptors. The activity profiles of different disulfide-crosslinked p75NTR mutants were similar but not identical, suggesting that different configurations of p75NTR dimers might be endowed with different functions. Interestingly, crosslinked p75NTR mutants did not mimic the effects of the myelin inhibitors Nogo or MAG, suggesting the existence of ligand-specific activation mechanisms. Together, these results support a conformational model of p75NTR activation by neurotrophins, and reveal a genetic approach to generate gain-of-function receptor variants with distinct functional profiles.
|
|
